CERE 120
Alternative Names: AAV-NRTN; AAV-NTN; AAV2-neurturin; AAV2-NTN; CERE-120; Neurturin gene therapyLatest Information Update: 31 Mar 2022
At a glance
- Originator Ceregene
- Developer Sangamo BioSciences
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Nerve tissue protein modulators; Neurturin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders; Huntington's disease; Parkinson's disease
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in United Kingdom (Intrastriatal)
- 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in USA (Intrastriatal)